Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...

PAH treatments show similar efficacy in reducing morbidity/mortality in CHD-PAH and PAH patients, with a 50% risk reduction in CHD-PAH. Improvements in 6-minute walking distance and NT-proBNP levels ...

Ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension by 55%, according to recent study results.

Lindsay talks about the difficult road of managing a pulmonary arterial hypertension diagnosis, and how a newly discovered ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that British Columbia, Non-Insured Health Benefits (NIHB), Nova Scotia, Quebec and Veterans Affairs Canada (VAC ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

Congenital heart disease and pulmonary arterial hypertension (PAH) associated with congenital heart disease can be immediately detected using chest radiograph-based artificial intelligence (AI), a ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients helped delay serious outcomes in the ZENITH trial. Among 172 patients ...

Pulmonary arterial hypertension, a disease that leads to worsening lung and heart problems that eventually become life-threatening, is treated with drugs that alleviate symptoms. FDA approval of a new ...

A new phase 3 study comparing mono and duo therapies may yield greater guidance and treatment options for children with pulmonary arterial hypertension (PAH). PAH is a rare condition in children, but ...

Please provide your email address to receive an email when new articles are posted on . The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension ...